[HTML] cell.comFull View

[HTML][HTML] MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell reports, 2015 - cell.com
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …
被引用次数：152 相关文章

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Golfman, P North, JC Mulloy, O Gonzalo… - 2015 - zaguan.unizar.es
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell …, 2015 - pubmed.ncbi.nlm.nih.gov
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …
[PDF] scienceopen.com

[PDF][PDF] MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell …, 2015 - scienceopen.com
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell …, 2015 - ohiostate.elsevierpure.com
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell …, 2015 - einstein.elsevierpure.com
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …
[HTML] sciencedirect.com

[HTML][HTML] MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell Reports, 2015 - Elsevier
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …

[引用][C] MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell Reports, 2015 - cir.nii.ac.jp
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation
and Are Sensitive to the BCL-2-Specific Antagonist ABT-199 | CiNii Research CiNii 国立情報学 …
[PDF] psu.edu

[PDF][PDF] MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell Reports, 2015 - Citeseer
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …
[PDF] core.ac.uk

[PDF][PDF] MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

JM Benito, L Godfrey, K Kojima, L Hogdal… - Cell Reports, 2015 - core.ac.uk
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers
are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as …